- Provectus ( OTC:PVCT ) said it had expanded its sponsored research program with Michio Kurosu, Professor at the University of Tennessee Health Science Center to investigate its pharmaceutical-grade rose bengal to treat anti-fungal and anti-oral bacterial infections.
- The Kurosu team plans to evaluate the in vitro activity of Provectus’ rose bengal against different fungal strains and to conduct susceptibility tests against fungal and bacterial mouth microbes.
For further details see:
Provectus Biopharma partners to test rose bengal as anti-fungal and anti-oral bacterial agent